title: Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6.
abstract: OBJECTIVE
  To investigate the potential association between serum inflammatory cytokine levels and thyroxine replacement dose in patients with Hashimoto disease.
  
  
  METHODS
  The study included 40 patients (12 men) with a mean age of 56.52+/-6.12 years who had hypothyroidism due to Hashimoto disease. Serum interleukin-1b (IL-1b), tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) levels, as well as TSH, T(3) and T(4) were measured (ELISA).
  
  
  RESULTS
  Serum IL-6 showed a significant positive correlation both with total thyroxine replacement dose (r=0.551, p=0.001) and with dose per kilogram of body weight (r=0.482, p=0.002). There was also a significant negative linear correlation between serum IL6 and T(3) (r=-0.322, p=0.043), as well as between serum IL6 and T(3)/T(4) ratio (r=-0.332, p=0.036). A further significant (r=0.419, p=0.007) positive association was demonstrated between IL6 and TNF-alpha. However, no association was found between T(3) or T(3)/T(4) ratio and TNF-alpha or IL1b.
  
  
  CONCLUSIONS
  In patients with Hashimoto disease serum IL-6 levels are positively associated with thyroxine replacement dose and negatively associated with T(3) and T(3)/T(4) ratio. These results are possibly attributable to the inhibitory effect of IL6 on deiodination of T(3) and imply a role for IL6 in determining thyroxine replacement dose among these patients.
authors.affiliation: Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. papanasniko@yahoo.gr
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papanas
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Papazoglou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Papatheodorou
authors.forename: Christos
authors.initials: C
authors.lastname: Antonoglou
authors.forename: Stamatia
authors.initials: S
authors.lastname: Kotsiou
authors.forename: Efstratios
authors.initials: E
authors.lastname: Maltezos
mesh_terms: D004305:Dose-Response Relationship, Drug; D005260:Female; D050031:Hashimoto Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013974:Thyroxine / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: C508600:IL6 protein, human; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D014284:Triiodothyronine; D013974:Thyroxine